PO.TB03.02 · 肿瘤生物学

淋巴管系统作为肿瘤发生的非遗传性驱动因素

Lymphatic vasculature as a non-genetic driver of tumorigenesis

编号 4827 展板 1 时间 4/21 09:00–12:00 区域 Section 27 主讲 Celeste Kanne, MS
分会场 Epithelial-to-Mesenchymal Transition
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Celeste K. Kanne, Jeremy Horrell, Hodaya Knafo, Savannah Martin, Aditya Verma, Ananya Goyal, Madison Conte, Shiri Gur-Cohen

University of California San Diego, La Jolla, CA

摘要 Abstract

中文摘要
携带具有致癌潜能的基因突变很常见,但并非每个人都会发展为癌症。这提示非遗传性因素促进肿瘤起始和进展。在鳞状细胞癌(SCC)等上皮性癌症中,干细胞表现出可塑性,通过上皮-间充质转化从上皮身份转变为间充质身份,这一过程与转移相关。淋巴管系统以其在体液平衡和免疫运输方面的作用而闻名,也支持干细胞微环境。鉴于这一动态特性,我们假设淋巴管可能代表一种通过改变干细胞行为来驱动癌症进展的非遗传性因素。为表征良性肿瘤与晚期肿瘤中的淋巴管排列,我们对光学透明化的良性乳头状瘤和进展的皮肤SCC进行了高分辨率3D整体免疫荧光成像。与乳头状瘤相比,晚期SCC表现出更高的淋巴管关联和整合。空间转录组学显示,富含淋巴信号的区域与SCC中表达杂合上皮-间充质状态的区域一致,提示淋巴管定位有助于确定这些过渡性肿瘤状态的空间结构。为检验淋巴管是否为肿瘤进展所必需,我们使用了皮肤SCC的化学和遗传(SOX9-CreER;Kras mut;p53 fl/fl;YFP fl/fl)小鼠模型。经受局部淋巴功能障碍的肿瘤大小稳定或消退,而匹配的对照组则持续进展。免疫荧光显示消退肿瘤中上皮身份增加、间充质身份减少,与向更上皮化和治疗反应性状态的转变一致。这些发现提示淋巴信号塑造了控制肿瘤细胞演变的调控程序。为界定这些程序,我们使用单细胞RNA测序分析了乳头状瘤和SCC。分析解析出不同的上皮、杂合和间充质状态。杂合状态作为关键的转变点出现,其特征为具有促淋巴特征的分泌因子的选择性诱导,提示其在将淋巴信号与肿瘤细胞演变和恶性进展联系起来方面具有潜在作用。使用荧光慢病毒报告基因,我们证实该分泌信号在体内晚期肿瘤中高度表达。在功能上,在源自肿瘤起始细胞的肿瘤中沉默该促淋巴信号可减缓进展,证明其在驱动肿瘤发生中的活跃作用。总之,这些发现揭示淋巴管与肿瘤起始细胞的相互作用构成SCC中的一个核心调控轴,将淋巴管系统定位为一个有前景的治疗切入点以遏制恶性进展。
查看英文原文 English abstract
Harboring genetic mutations with oncogenic potential is common, yet not everyone develops cancer. This suggests that non-genetic factors contribute to tumor initiation and progression. In epithelial cancers such as squamous cell carcinoma (SCC), stem cells exhibit plasticity, transforming from an epithelial to a mesenchymal identity through the epithelial-to-mesenchymal transition, a process linked to metastasis. The lymphatic vasculature, known for fluid balance and immune trafficking, also supports the stem cell niche. Given this dynamic, we hypothesized that lymphatic vessels may represent a non-genetic element that drives cancer progression by altering stem cell behavior. To characterize lymphatic arrangement in benign versus advanced tumors, we performed high resolution 3D whole-mount immunofluorescence imaging on optically cleared benign papillomas and progressed skin SCCs. Compared to papillomas, advanced SCCs exhibited greater lymphatic association and integration. Spatial transcriptomics showed that regions enriched for lymphatic signals aligned with domains expressing hybrid epithelial-mesenchymal states in SCCs, suggesting that lymphatic positioning helps define the spatial architecture of these transitional tumor states. To test whether lymphatic vessels are required for tumor progression, we used both chemical and genetic (SOX9-CreER; Kras mut ; p53 fl/fl ; YFP fl/fl ) mouse models of skin SCC. Tumors subjected to local lymphatic dysfunction stabilized or regressed in size, while matched controls continued to progress. Immunofluorescence revealed increased epithelial identity and reduced mesenchymal identity in regressing tumors, consistent with a shift toward a more epithelial and therapeutically responsive state. These findings suggest that lymphatic cues shape the regulatory programs governing tumor cell evolution. To define these programs, we profiled papillomas and SCCs using single cell RNA sequencing. The analyses resolved distinct epithelial, hybrid, and mesenchymal states. The hybrid state emerged as a key transition point, marked by selective induction of a secreted factor with a pro-lymphatic signature, suggesting a potential role in linking lymphatic cues to tumor cell evolution and malignant progression. Using a fluorescent lentiviral reporter, we confirmed that the secreted cue becomes highly expressed in advanced tumors in vivo . Functionally, silencing the pro-lymphatic cue in tumors derived from tumor-initiating cells slowed progression, demonstrating its active role in driving tumorigenesis. Together, these findings reveal that lymphatic interactions with tumor-initiating cells form a central regulatory axis in SCC, positioning the lymphatic vasculature as a promising therapeutic entry point to restrain malignant progression.
利益披露 Disclosure
C. K. Kanne, None.. J. Horrell, None.. H. Knafo, None.. S. Martin, None.. A. Verma, None.. A. Goyal, None.. M. Conte, None.. S. Gur-Cohen, None.

← 返回 AACR 2026 检索